The following table summarizes for each of the Named Officers option exercises during the 2003 fiscal year, including the aggregate value of gains on the date of exercise, the total number of unexercised options for Ordinary Shares, if any, held at December 31, 2003 and the aggregate number and dollar value of unexercised in-the-money options for Ordinary Shares, if any, held at December 31, 2003. The value of unexercised in-the-money options at fiscal year-end is the difference between the exercise or base price of such options and the fair market value of the underlying Ordinary Shares on December 31, 2003, which was US $1.35 per share. Actual gains, if any, upon exercise will depend on the value of Ordinary Shares on the date of any exercise of options.
At the 2002 and 2003 Annual General Meetings of Shareholders, the shareholders approved for each director (other than the Chairman and Vice-Chairman), a cash retainer fee for participation in meetings of the Board of Directors or any committee of US $2,500 per calendar quarter. Directors are not entitled to receive any additional per-meeting fee, but will be reimbursed for their reasonable travel and accommodation expenses. In addition, the shareholders approved a future annual option grant of 10,000 options to each director and 50,000 options to each of the Chairman and Vice Chairman of the Board. The Chairman of the Board of Directors, Prof. Frenkel, and the Vice Chairman of the Board of Directors, Mr. Arie Genger, are each entitled to an advisory fee of up to US $120,000 per year. Shareholder approval for the compensation terms of the Company’s directors is sought annually, at the Company’s Annual General Meeting. The Company intends to seek such approval for 2004 when it holds its 2004 Annual General Meeting.
Employment Agreements, Termination Provisions and Change in Control Provisions
Employment Agreement with Mr. Avner Raz
Mr. Raz has entered into an employment Agreement with the Company, dated April 24, 2003 (“Raz Agreement”), pursuant to which effective as of June 20, 2003, Mr. Raz was appointed as the Company’s Chief Executive Officer (“Commencement Date”) for a 4-year term (“Term”), and effective from April 28, 2003, Mr. Raz was appointed as a member of the Company’s Board of Directors. Pursuant to the Raz Agreement, Mr. Raz is entitled to an annual base salary of US $530,000. In addition, for 2003, Mr. Raz was entitled to a minimum guaranteed bonus of US $250,000 which was not conditioned on any performance criteria, which was paid in 2004. Mr. Raz was also entitled to an additional bonus, based on the performance criteria as set by the Board of Directors and linked to the performance bonuses payable to the current senior executives of the Company, not exceeding US $250,000. This additional bonus was not paid for 2003. Furthermore, Mr. Raz was entitled to a one-time cash payment of US$270,000 as a signing bonus.
Mr. Raz was granted on April 24, 2003 options to purchase up to 400,000 of the Company’s Ordinary Shares, which grant was approved at the Company’s 2003 Annual General Meeting. The exercise price of the options is US $1.205 per share, reflecting the 30-day average closing price of the Company’s Ordinary Shares on the NASDAQ prior to the date of grant. The options vest over 48 months as follows: 133,336 options vest at the end of the first 12 months of employment, following which an additional amount of 22,222 options vest at the end of each three month period, consecutively. On April 20, 2004, Mr. Raz was granted options to purchase up to an additional 425,000 Ordinary Shares, subject to shareholder confirmation as set forth in Proposal 2 above – “Ratification, Confirmation and Approval of the Option Grant to Mr. Avner Raz to Purchase up to 425,000 Ordinary Shares of the Company”. In addition, the Raz Agreement provides for all benefits, such as Management Insurance Fund, Advance Study Fund and medical and dental insurance, as are generally granted to the Company’s senior executives.
If the Raz Agreement and Mr. Raz’s employment are terminated by (i) the Company (ii) by Mr. Raz if the Company files for bankruptcy, becomes or is declared insolvent or due to a change in control (as such term is defined in the Company’s 2000 Share Option Plan) or (iii) by Mr. Raz upon a material deterioration in his employment terms, Mr. Raz will be entitled to a sum equal to the compensation (including bonuses and other benefits) that he would have been paid if he had continued working for the Company for the full Term. In addition, all previously unvested options shall be accelerated and fully vest.
- 16 -
The Company’s monetary undertakings under the Raz Agreement are secured by a bank guarantee issued by Bank Hapoalim B.M. in the initial amount of US$3,000,000. The amount of the guarantee declines over time as follows: on June 20, 2004, the guaranteed amount was reduced by US$800,000. Thereafter, the guaranteed amount will be reduced by US$733,333 on June 30, 2005, 2006 and 2007 and the guarantee will terminate on August 5, 2007.
The Raz Agreement also includes confidentiality and non-competition provisions.
For information regarding Mr. Raz’s security ownership, see “Security Ownership of Certain Beneficial Owners and Management” herein.
Employment Agreement with Mr. Kevin Morano
Mr. Morano has entered into an employment agreement with the Company and Lumenis Inc., dated as of January 21, 2003, effective as of March 1, 2002 (the “Morano Agreement”). The Morano Agreement is terminable at the option of either party upon 90 days prior notice. Pursuant to the Morano Agreement, Mr. Morano served as the Chief Financial Officer of the Company and Lumenis Inc. The Morano Agreement provided for an annual base salary of US $250,000, to be reviewed from time to time by the CEO. The base salary was later increased to US $300,000. In addition, Mr. Morano is entitled to a bonus equal to 100% of his annual base salary if 100% of targets are met, and received a bonus of US $50,000 for 2003. The Morano Agreement provides for all benefits, such as life insurance, medical and dental insurance, disability insurance, certain saving programs and participation in the Company’s 401K plan, as are generally granted to the Company’s senior executives. The Morano Agreement also includes confidentiality and non-competition terms and conditions.
An addendum to the Morano Agreement was entered into on March 22, 2004 (the “Morano Addendum”). Pursuant to the Morano Addendum, Mr. Morano serves, effective August 1, 2004, as the Company’s and Lumenis Inc. Senior Vice President for Marketing and Business Development, under the same salary and benefits provided in the Morano Agreement.
Under the Morano Addendum, in case of termination of employment by the Company other than for cause; an event of change of control (as such term is defined in the Company’s 2000 Share Option Plan) of the Company; a mutual decision by the parties that Mr. Morano is not suitable to perform his duties; or if Mr. Morano resigns following the Audit Committee’s determination that Mr. Morano’s duties are materially diminished, he is required to relocate, or payments and benefits to him are reduced, then (1) the Company and Lumenis Inc. shall pay Mr. Morano his base salary and all employment and fringe benefits, for the period from date of such termination through April 20, 2007, as well as a participation bonus for the period of employment during the calendar year in which termination occurs and for which bonus is granted; and (2) all options granted to Mr. Morano during the course of employment, whether vested or unvested, will become immediately vested and will remain exercisable for the remaining lifetime of the options in accordance with the Share Option Plan.
- 17 -
The Addendum further provides that the term “cause” with respect to a termination of Mr. Morano’s employment by the Company, shall not include any event related to Mr. Morano’s service as the Company’s Chief Financial Officer, provided such event does not involve Mr. Morano’s performance of a criminal felony resulting in a personal financial benefit.
For information regarding Mr. Morano’s security ownership, see “Security Ownership of Certain Beneficial Owners and Management” herein.
Employment Agreement with Ms. Lauri Hanover
Ms. Hanover has entered into an employment agreement with the Company, dated April 20, 2004, which became effective as of August 1, 2004 (the “Hanover Agreement”). Pursuant to the Hanover Agreement, Ms. Hanover serves as the Chief Financial Officer of the Company. The Hanover Agreement is terminable at the option of either party upon 90 days prior notice. In the event of termination of Ms. Hanover’s employment by the Company, Ms. Hanover will be entitled to base salary payments and benefits, as follows: (i) during the prior notice period, (ii) a lump sum severance payment pursuant to the Israeli Severance Payment Law, 5723-1963, (iii) base salary and benefits for a 12-months period, and (iv) a participation bonus pro rata for the period for which she was employed in the Company during the calendar year in which termination occurs and for which bonus is granted. The Hanover Agreement provides for an annual base salary of $250,000, to be reviewed from time to time by the Company. In addition, Ms. Hanover is entitled to a bonus equal to 100% of her annual base salary if 100% of targets are met. Ms. Hanover was granted options to purchase 100,000 Ordinary Shares, exercisable in four equal installments every anniversary following the date of grant, with the first installment vesting on April 20, 2005. The Hanover Agreement further provides for future grants of options as shall be determined by the Company. The Hanover Agreement provides for all benefits, such as life insurance, medical insurance, disability insurance, certain saving programs, as are generally granted to the Company’s senior executives. The Hanover Agreement also includes confidentiality and non-competition terms and conditions.
Employment Agreement with Mr. Alon Maor
Effective August 3, 2001, the Company entered into an employment agreement with Mr. Alon Maor (the “Maor Agreement”) pursuant to which Mr. Maor served as Executive Vice President of the Aesthetic Business Unit. The Maor Agreement is terminable by either party upon the provision of six-months’ prior notice, and otherwise terminates three years after the effective date. Following the Company’s notice of termination, the Maor Agreement was terminated on December 31, 2003.
Pursuant to the Maor Agreement, Mr. Maor received in 2003 an annual base salary in the amount of US $200,000, an annual housing allowance equal to his actual rent, but subject to an annual maximum of US $96,000, an annual allowance for the education of his children from pre-school through high school (subject to a tax gross up), and all benefits, such as life insurance, medical and dental insurance disability insurance, and certain saving programs, as were granted to the Company’s senior executive officers.
In addition, Mr. Maor was to be awarded an annual bonus of 90% of his annual base salary payment if the Aesthetic Business Unit met certain annual targets mutually agreed upon by the Chief Executive Officer and Mr. Maor. The Maor Agreement further provided that if achievement of the goals exceeded or was less than 100%, the percentage of base salary to be paid as bonus would correspondingly be increased in excess of or decreased below the set 90%. No annual bonus was paid in 2003.
- 18 -
The Maor Agreement also included confidentiality and non-competition terms and conditions.
As part of the termination of the Maor Agreement, Mr. Maor is entitled to nine-months’ salary payments following the date of termination.
For information regarding Mr. Maor’s security ownership, see “Security Ownership of Certain Beneficial Owners and Management” herein.
Employment Agreement with Mr. Wade Hampton
Mr. Wade Hampton first joined the Company in May 2001 and left in November of that year. Effective February 3, 2003, Mr. Wade Hampton rejoined the Company as Vice President of Americas Sales for Medical Business (Ophthalmic, Surgical and Refractive). In this position, Mr. Hampton received an annual base salary in the amount of US $170,000 and was entitled to a performance-based bonus of US $70,000 and a retention payment of US $40,000. Mr. Wade also received a US $25,000 one-time signing bonus. On February 3, 2003, the Company granted Mr. Hampton an option to purchase 50,000 Ordinary Shares of the Company, with an exercise price equal to the closing price of the Company’s Ordinary Shares on the date of grant of US $1.20. The options expire on February 3, 2008, and vest over three years, in three equal installments on each anniversary of their grant. On November 11, 2003, Mr. Hampton’s employment terms were amended and his annual salary was increased to US $236,000. The annual bonus was increased to US $118,000, subject to achievement of certain performance targets and other criteria. In addition, the Company granted Mr. Hampton additional options to purchase up to 100,000 Ordinary Shares under the 2000 Share Option Plan, at an exercise price of US $1.89. The term of the options is eight years from the date of grant, with a post termination exercise period of 90 days. The options vest in three equal annual installments, commencing on October 27, 2004 and thereafter on the first and second anniversaries following such date.
For information regarding Mr. Hampton’s security ownership, see “Security Ownership of Certain Beneficial Owners and Management” herein.
Employment Agreement with Mr. Zhai QiYing
Effective on May 1, 2003, Mr. Zhai QiYing entered into an employment agreement with the Company (the “QiYing Agreement”). Pursuant to the QiYing Agreement, Mr. QiYing serves as the Vice President for China and APAC Sales and Service of the Company. The QiYing Agreement provides for an annual base salary of US $150,000. In addition, Mr. QiYing is entitled to a bonus equal to total amount of US$160,000 subject to achievement of certain revenue and expenses targets as per the approved budget for China and APAC, as well as on the Company meeting its financial targets. On May 12, 2003, the Company granted Mr. QiYing options to purchase up to 10,250 of the Company’s Ordinary Shares at an exercise price of US $1.77 per share. The term of the options is eight years from the date of grant with a post termination exercise period of 90 days. The options vest in four semi-annual installments, starting on November 12, 2003. In addition, on October 27, 2003, Mr. QiYing was granted options to purchase up to 30,000 of the Company’s Ordinary Shares at an exercise price of US $1.89 per share. The term of the options is eight years from the date of grant with a post termination exercise period of 90 days. The options vest in three equal annual installments, commencing on October 27, 2004.
- 19 -
For information regarding Mr. QiYing’s security ownership, see “Security Ownership of Certain Beneficial Owners and Management” herein.
Compensation Committee Interlocks and Insider Participation in Compensation Decisions
No member of the Board (which during 2003 and 2004 determined and determines executive compensation for the Company) is currently, or was at any time during the fiscal year ended December 31, 2003, an officer or employee of the Company, other than (i) Mr. Raz who serves, effective as of June 20, 2003 as the Company’s President and Chief Executive Officer (See description of Mr. Raz’s employment terms as Company’s President and Chief Executive Officer under “Employment Agreements, Termination Provisions and Change in Control Provisions” herein); (ii) Mr. Arie Genger who served as interim Chief Executive Officer from January 1, 2003 until June 19, 2003, and (iii) Dr. Darrell Rigel, a director, evaluates for the Company some of its products and applications, for the purpose of providing the Company with information on the use of its equipment by its physician customers and for use in developing new products or applications. The Company also pays Dr. Rigel US $2,000 per each Medical Advisory Group meeting which he chairs, plus expenses. The arrangement with Dr. Rigel was approved in the 2003 Annual General Meeting of Shareholders. No executive officer of the Company served on the board of directors or compensation committee of any entity that has one or more executive officers serving as members of the Company’s Board of Directors.
PROPOSALS OF SHAREHOLDERS
Under Rule 14a-8 of the Securities Exchange Act of 1934 (the “Exchange Act”), any shareholder of the Company who intends to present a proposal at the next Annual General Meeting of Shareholders and who wishes the proposal to be included in the Proxy Statement for such meeting must submit the proposal in writing to the Secretary of the Company, at the principal executive offices of the Company. The proposal must be received a reasonable period prior to the printing and mailing of the Company’s proxy materials for the meeting. The Company will announce the deadline for submission of such proposals in either a Current Report on Form 8-K or a Quarterly Report on Form 10-Q.
Shareholders who do not desire to comply with the requirements of Rule 14a-8, must satisfy the requirements of the Companies Law in order to have a proposal presented at the Annual General Meeting. Under the Companies Law, only shareholders who hold at least one percent (1%) of the outstanding voting rights are entitled to request that the Board of Directors of the Company include a proposal, at a future shareholders meeting, provided that such proposal is appropriate to be discussed at such meeting.
Rule 14a-4(c) of the Exchange Act governs the Company’s use of its discretionary proxy voting authority with respect to a matter that is not addressed in the Company’s Proxy Statement for an Annual General Meeting of Shareholders. Rule 14a-4(c) provides that if the Company does not know, a reasonable time before the mailing of its proxy materials for the meeting, that a matter is to be presented at the meeting, then the Company will be allowed to use its discretionary voting authority when the proposal is raised at the meeting, without any discussion of the matter in the proxy statement.
- 20 -
OTHER BUSINESS
The Board of Directors of the Company is not aware of any other matters that may be presented at the Special General Meeting other than those mentioned in the attached Company’s Notice of Special General Meeting of Shareholders. If any other matters do properly come before the Special General Meeting, it is intended that the persons named as proxies will vote, pursuant to their discretionary authority, according to their best judgment in the interests of the Company.
By Order of the Board of Directors,
—————————————— Avner Raz President and Chief Executive Officer |
Yokneam, Israel
_________, 2004
- 21 -
Annex A
[8-K (Amendment No.1 ) filed on May 25, 2004, together with copy of Deloitte letter–as filed]
- I -